Prevent Biometrics Releases 2.0 Version of Their Smart Mouthguard as Company Makes Push for Increased Soccer and Basketball Usage
Prevent Biometrics has released a 2.0 version of its sensor-embedded mouthguard to monitor head impacts that’s 60% smaller than the incumbent product. The product launch comes as Prevent Biometrics is providing its smart mouthguards to women’s national team rugby players during the ongoing World Cup in New Zealand.
Advanced NanoTherapies’ SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease
LOS GATOS, CA – September 19th, 2022 – Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant challenges through the creative applications of nanotechnology, today announced the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its SirPlux Duo Drug-Coated Balloon (DCB) for coronary artery disease in vessels less than 3.0mm. This achievement comes only weeks after the company received two other critical Breakthrough Device designations for its SirPlux Duo DCB in coronary in-stent restenosis (ISR) and peripheral below-the-knee (BTK) lesions.
Cleveland Clinic-Led Trial Finds That Cerebral Embolic Protection Device Reduced Risk of Disabling Stroke Following TAVR Procedure
Findings from a Cleveland Clinic-led trial show that a Cerebral Embolic Protection (CEP) device reduced the risk of disabling strokes by capturing and removing tiny pieces of calcium and other fragments resulting from transcatheter aortic valve replacement (TAVR) before they can reach the brain.
Imaging advances, targeted therapies improve outlook for recurrent pericarditis
Advances in imaging techniques and new treatments are changing the management of recurrent pericarditis, improving outcomes for patients with formerly treatment-resistant disease, researchers reported.
New VR Platform Fuses Physical and Virtual Worlds in Parkinson’s Disease and Beyond
Recently scientists at Cleveland Clinic have developed a solution to the locomotion problem and have created a truly immersive VR experience. They are initiating research to use their platform to understand and better treat freezing of gait in patients with Parkinson’s disease (PD). Future research plans include use of the platform for early identification of PD and other neurodegenerative disorders in older adults.
Prevent Biometrics Confirmed as Instrumented Mouthguard Provider for a Study During the 2022-23 Season
The RFU, Premiership Rugby and World Rugby confirm that Prevent Biometrics has been selected as the instrumented mouthguard (iMG) provider for a study with Premiership Rugby, Allianz Premier 15s and England representative teams for the 2022-23 season. A comprehensive procurement process took place to select the instrumented mouthguard provider for this study, which included a review of the validation work undertaken by the Rugby Football League in partnership with Leeds Beckett University in their pilot study for the TACKLE project.
30 Great Chief Innovation Officers to Know | 2022
Chief innovation officers have become vital to digital transformation efforts and initiatives to keep health systems on the cutting edge of delivering patient care. Innovation chiefs are tasked with creating a culture of innovation across the system, accelerating research and development and managing venture capital funds. They also oversee efforts to harness the ingenuity and creativity of team members to improve operations and clinical care.
Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing
Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease's most significant challenges through the creative applications of nanotechnology, today announced the closing of its oversubscribed $7.2 million Series A equity financing, marking a total of $12.5 million raised since September 2020. Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo drug-coated balloon (DCB) in de-novo coronary artery disease (CAD) lesions. Funding comes from various sources in the U.S., Canada, Europe, and Asia.
GE Healthcare joins $33M funding for Cleveland Clinic spinout Centerline Biomedical
With FDA clearance for its flagship product secured and a U.S. launch under way, Centerline Biomedical’s current focus is twofold: bringing its surgical navigation technology into more operating rooms around the world and expanding its indications into a broader range of surgical procedures.
The task of juggling that dual focus just got somewhat smoother, as Centerline announced on Monday the close of a series B equity financing that’ll bolster all of its ongoing endeavors.
Astrotech Subsidiary and Cleveland Clinic Expand Breath Analysis Study to Detect Multiple Diseases
Astrotech Corporation’s (NASDAQ: ASTC) subsidiary, BreathTech Corporation, announced today that it has amended its Joint Development and Option Agreement with Cleveland Clinic to include additional areas of focus. Under the amended agreement, ongoing work around development of a rapid breath test for COVID-19 will be expanded to utilize BreathTech’s core mass spectrometry technology to screen for a variety of diseases spanning the entire body. The project will focus on detecting bloodstream infections, respiratory infections such as influenza types A and B and respiratory syncytial virus (RSV), carriage of Staphylococcus aureus, and Clostridioides difficile (C. diff) infections.